AAVantgarde Bio
PrivateLast Round
Series B
Nov 3, 2025
Total Funding Raised
$211.5M
Company Overview
AAVantgarde Bio operates in Healthcare & Life Sciences and is based in Milan. Its latest recorded funding round was a Series B round in November 2025.
AAVantgarde Bio is a biotechnology company that develops gene therapies for inherited retinal disorders using proprietary Adeno-Associated Viral (AAV) vector platforms to deliver large genes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AAVantgarde Bio Comparables
Compare AAVantgarde Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| SpliceBio | 89% | |
| Atsena Therapeutics | 86% | |
| Coave Therapeutics | 83% |
For institutional investors. Book with your work email.
AAVantgarde Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 3, 2025 | ||||
| Series A | Jun 6, 2023 | ||||
| Seed | Jun 30, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
AAVantgarde Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forbion Capital Partners | Series A |
| Sixty Degree Capital | Series B |
| XGEN Venture | Series B |
| Forbion | Series A, Series B |
| Neva SGR | Series B |
| Athos KG | Series B |
| Accomplice | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 12, 2026
Will present at the 44th Annual J.P. Morgan Healthcare Conference.
- Nov 3, 2025
$141M round completed.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventNov 12, 2026
AAVantgarde Bio S.r.l. presents its dual-AAV MYO7A gene therapy program for Usher syndrome type 1B at the FLORetina-ICOOR 2026 Meeting in Italy from Dec 3rd-6th '26.
- attends_eventOct 4, 2026
AAVantgarde Bio S.r.l. will showcase clinical progress in Usher syndrome type 1B and Stargardt disease at EURetina 2026 in Austria in Oct '26, including updated LUCE-1 clinical data and preclinical data and the CELESTE study design.
- attends_eventOct 4, 2026
AAVantgarde Bio S.r.l. announced it will present updated clinical data from the LUCE-1 study and preclinical and clinical development data for AAVB-039 at the 26th European Society of Retina Specialists (EURETINA) Annual Congress in Austria from Oct 1st-4th '26.
- attends_eventSep 16, 2026
AAVantgarde Bio S.r.l. plans to present at the Ophthalmology Futures Forum in Austria on Sep 30th '26.
- hiresSep 1, 2026
On Sep 1st '26, AAVantgarde Bio S.r.l. appoints Megan Zoschg Canniere as Chief Regulatory & Quality officer to support its clinical-stage pipeline and regulatory strategy.
For institutional investors. Book with your work email.
AAVantgarde Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about AAVantgarde Bio's valuation, stock price, and market status.
Is AAVantgarde Bio a public or private company?
AAVantgarde Bio is a private company.
What is the current stock price of AAVantgarde Bio?
AAVantgarde Bio is a private company, so its shares have no public market price. Caplight tracks AAVantgarde Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is AAVantgarde Bio worth (valuation)?
Valuation information for AAVantgarde Bio is not publicly available.
Can I buy AAVantgarde Bio stock?
AAVantgarde Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was AAVantgarde Bio's last funding round?
AAVantgarde Bio's most recent funding round was Series B on November 3, 2025.
Who are the main investors in AAVantgarde Bio?
Key investors in AAVantgarde Bio include Forbion Capital Partners, Forbion, Accomplice, Sofinnova Partners, Atlas Venture.
Will AAVantgarde Bio IPO soon?
No public IPO plans have been announced for AAVantgarde Bio.
How can I track AAVantgarde Bio secondary market activity?
Caplight tracks bids, offers, and trades in AAVantgarde Bio's shares on secondary markets.